Royal Philips and BioIntelliSense are set to receive about $2.8m funding from the US Department of Defense (DoD) to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of symptoms related to Covid-19.
The US Army Medical Research and Development Command (USAMRDC) has selected the companies to receive the funding.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies will get the funding through a Medical Technology Enterprise Consortium (MTEC) award.
It aims to speed up the usage of wearable diagnostics that would benefit military and public health through the early detection and containment of pre-symptomatic Covid-19 cases.
Working with the University of Colorado Anschutz Medical Campus, the clinical study will have 2,500 eligible subjects with a recent, known exposure to Covid-19 and/or early symptoms of the disease.
As part of the study, BioIntelliSense’s medical grade wearable BioSticker will be validated for early detection of Covid-like symptoms.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe research will also focus on the assessment of scalability, reliability, software interface and user environment testing.
Philips North America chief market leader and executive committee member Vitor Rocha said: “To turn the tide on Covid-19, the public and private sectors need to use every available tool in their arsenal, which includes looking at new ways of how we can create solutions for early disease detection.
“No one organisation will be able to combat Covid-19 alone, but working together, we hope to develop a solution that will allow people to understand if they are in the early stages of illness, and take the appropriate actions to help limit spread and get the treatment they need.”
The study will leverage BioSticker, which aids in uninterrupted multi-parameter vital signs monitoring for 30 days.
It also collects data across various set of vital signs, physiological biometrics and symptomatic events, including those linked to Covid-19.
Its integration into Philips’ remote patient monitoring offerings shows how cloud-based data collection happens seamlessly, across different settings, from the hospital to the home.
